Drugs / Ad5-yCD/mutTKSR39rep-hIL12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02555397 | Aug 2015 → Jun 2019 | prostate cancer | Henry Ford Health System | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-yCD/mutTKSR39rep-hIL-12 | “In a phase I dose escalation and safety study (NCT02555397), a replication-competent oncolytic adenovirus expressing yCD, TK and hIL-12 (Ad5-yCD/mutTKSR39rep-hIL-12) was...” PMID 37713401 ↗ Sep 2023 |
| Known as | Ad5-IL-12 | “This trial confirmed that replication-competent Ad5-IL-12 adenovirus (Ad5-yCD/mutTKSR39rep-hIL-12) was well tolerated when administered locally to prostate tumors.” PMID 37713401 ↗ Sep 2023 |
| Route | Other | “Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1” NCT02555397 ↗ |